# Ever Supreme Bio Technology

Source: https://onco.cc/companies/ever-supreme-bio-technology/  
OnCo record `ever-supreme-bio-technology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ever Supreme Bio Technology is a Taiwanese company developing immune cell and stem cell medicines. Its cancer medicine, CAR001, uses donor immune cells built to find tumours, and the FDA gave it orphan drug status for malignant glioma in 2026.

## Summary

Ever Supreme Bio Technology Co., Ltd., based in Taichung, was founded in 2016 by Dr Chang-Hai Tsai, according to the company, and works on immune cell, stem cell, nanoparticle and exosome technology platforms. Its lead cancer product, CAR001, is described by the company as an allogeneic CAR.BiTE gamma delta T-cell therapy that needs no leukapheresis, lymphodepletion or HLA matching. The company reports that the phase 1 part of its phase 1/2a trial (NCT06150885) treated 15 patients with relapsed or refractory colorectal cancer, glioblastoma, triple-negative breast cancer or non-small cell lung cancer, with one complete response in recurrent glioblastoma, and that the safety committee approved the phase 2a expansion in mid-2026. On 21 September 2026 the FDA granted orphan drug designation for malignant glioma to allogeneic gamma delta T cells modified by mRNA encoding a VHH-based CAR targeting HLA-G and a secretable BiTE targeting PD-L1.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Ever Supreme Bio Technology Co., Ltd.; Ever-Supreme; Ever Supreme Bio Technology, Co. Ltd.
- HQ: Taichung
- Type: cell-therapy
- Website: https://en.ever-supreme.com.tw/

## Notes

- The FDA record describes the product without naming CAR001; the description matches the company's account of CAR001 and the HLA-G-CAR.BiTE cells in NCT06150885. The company's efficacy figures are its own. No HLA-G target record exists in the corpus. Read on 4 November 2026.

## Sources

- Official website: https://en.ever-supreme.com.tw/
- CAR001 phase 1 completion, July 2026: https://en.ever-supreme.com.tw/news_detail/39
- CAR001 at BIO Asia-Taiwan, July 2026: https://en.ever-supreme.com.tw/news_detail/41
- FDA orphan designation, malignant glioma, 21 September 2026: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1176726

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Gamma-delta T cell therapy](https://onco.cc/technologies/gamma-delta-t-cell-therapy/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [CAR001](https://onco.cc/drugs/car001/)
- trials: [A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors](https://onco.cc/trials/nct06150885/)

---
JSON: https://onco.cc/api/v1/entities/ever-supreme-bio-technology.json